Evidence map›Paper›PMID 34399367›Full record

ArticleRespiratory medicine2021

Genomic biomarkers in chronic beryllium disease and sarcoidosis.

Nancy W Lin, Lisa A Maier, Margaret M Mroz, Sean Jacobson, Kristyn MacPhail, Sucai Liu, Zhe Lei, Briana Q Barkes, Tasha E Fingerlin, Nabeel Hamzeh and 5 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Immune regulation by CD55 in chronic beryllium disease.American journal of respiratory cell and molecular biology · 2026
    Article
  2. Article
  3. Overview of multi-omics approaches for pulmonary sarcoidosis.EC pulmonology and respiratory medicine · 2025
    Article
  4. Review
  5. A Promising Biomarker for Pulmonary Sarcoidosis That Must Cross the Finish Line.American journal of respiratory and critical care medicine · 2024
    Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Nancy W LinDepartment of Medicine, University of Colorado, Aurora, CO, USA. Electronic address: nancy.lin@cuanschutz.edu.
Lisa A MaierDepartment of Medicine, University of Colorado, Aurora, CO, USA; Department of Medicine, National Jewish Health, Denver, CO, USA; Colorado School of Public Health, Aurora, CO, USA. Electronic address: lisamaier@njhealth.org.
Margaret M MrozDepartment of Medicine, National Jewish Health, Denver, CO, USA. Electronic address: mrozp@njhealth.org.
Sean JacobsonDepartment of Medicine, National Jewish Health, Denver, CO, USA. Electronic address: jacobsons@njhealth.org.
Kristyn MacPhailDepartment of Medicine, National Jewish Health, Denver, CO, USA. Electronic address: macphailk@njhealth.org.
Sucai LiuDepartment of Medicine, National Jewish Health, Denver, CO, USA. Electronic address: lius@njhealth.org.
Zhe LeiDepartment of Medicine, National Jewish Health, Denver, CO, USA; Department of Genetics, School of Biology and Basic Medical Science, Medical College of Soochow University, Suzhou, Jiangsu, China. Electronic address: leizhe@suda.edu.cn.
Briana Q BarkesDepartment of Medicine, National Jewish Health, Denver, CO, USA. Electronic address: barkesb@njhealth.org.
Tasha E FingerlinDepartment of Medicine, National Jewish Health, Denver, CO, USA; Colorado School of Public Health, Aurora, CO, USA. Electronic address: fingerlint@njhealth.org.
Nabeel HamzehDepartment of Medicine, University of Iowa, Iowa City, IA, USA. Electronic address: nabeel-hamzeh@uiowa.edu.
Annyce S MayerDepartment of Medicine, National Jewish Health, Denver, CO, USA; Colorado School of Public Health, Aurora, CO, USA. Electronic address: mayera@njhealth.org.
Clara I RestrepoDepartment of Medicine, National Jewish Health, Denver, CO, USA. Electronic address: restrepoc@njhealth.org.
Divya ChhabraDepartment of Medicine, National Jewish Health, Denver, CO, USA. Electronic address: ChhabraD@NJHealth.org.
Ivana V YangDepartment of Medicine, University of Colorado, Aurora, CO, USA; Department of Medicine, National Jewish Health, Denver, CO, USA. Electronic address: ivana.yang@cuanschutz.edu.
Li LiDepartment of Medicine, University of Colorado, Aurora, CO, USA; Department of Medicine, National Jewish Health, Denver, CO, USA. Electronic address: lil@njhealth.org.
National Jewish Health · USColorado School of Public Health · USUniversity of Colorado Anschutz Medical Campus · USUniversity of Iowa · US

Funding

Predictive Models of Beryllium Sensitization and Chronic Beryllium DiseaseR01ES034767 · NIEHS · NATIONAL JEWISH HEALTH · PI Maneesh Bhargava, Li Li · 2023 to 2026
$3.2M
Genetic Risk for Granulomatous Interstitial Lung DiseaseR01HL114587 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI FINGERLIN, TASHA E. · 2013 to 2018
$3.2M
Epigenetic Regulation of Immune Pathways in SarcoidosisR01HL140357 · NHLBI · NATIONAL JEWISH HEALTH · PI MAIER, LISA A, YANG, IVANA V · 2018 to 2021
$2.8M
Novel integrative approaches for disease phenotyping, utilizing radiomics in SarcoidosisR01HL142049 · NHLBI · NATIONAL JEWISH HEALTH · PI CARLSON, NICHOLE, FINGERLIN, TASHA E. · 2019 to 2022
$2.6M
Exposure in Epigenetic Regulation of Immune Response in CBDR01ES023826 · NIEHS · NATIONAL JEWISH HEALTH · PI MAIER, LISA A, YANG, IVANA V · 2015 to 2019
$2.3M
The immunoregulatory role of Alveolar Macrophages in Chronic Beryllium DiseaseR01ES025722 · NIEHS · NATIONAL JEWISH HEALTH · PI LI, LI · 2016 to 2020
$1.8M
Functional Genomics Approach to the Role of the JAK/STAT and MAPK Pathway in CBDK01ES020857 · NIEHS · UNIVERSITY OF COLORADO DENVER · PI LI, LI · 2011 to 2013
$382k
NHLBI NIH HHS R01 HL114587NHLBI NIH HHS R01 HL140357NHLBI NIH HHS R01 HL142049NIEHS NIH HHS K01 ES020857NIEHS NIH HHS R01 ES023826NIEHS NIH HHS R01 ES025722NIEHS NIH HHS R01 ES034767
6 · The paper itself

Abstract

Background Previous gene expression studies have identified genes IFNγ, TNFα, RNase 3, CXCL9, and CD55 as potential biomarkers for sarcoidosis and/or chronic beryllium disease (CBD). We hypothesized that differential expression of these genes could function as diagnostic biomarkers for sarcoidosis and CBD, and prognostic biomarkers for sarcoidosis. Study Design/Methods We performed RT-qPCR on whole blood samples from CBD (n = 132), beryllium sensitized (BeS) (n = 109), and sarcoidosis (n = 99) cases and non-diseased controls (n = 97) to determine differential expression of target genes. We then performed logistic regression modeling and generated ROC curves to determine which genes could most accurately differentiate: 1) CBD versus sarcoidosis 2) CBD versus BeS 3) sarcoidosis versus controls 4) non-progressive versus progressive sarcoidosis. Results CD55 and TNFα were significantly upregulated, while CXCL9 was significantly downregulated in CBD compared to sarcoidosis (p < 0.05). The ROC curve from the logistic regression model demonstrated high discriminatory ability of the combination of CD55, TNFα, and CXCL9 to distinguish between CBD and sarcoidosis with an AUC of 0.98. CD55 and TNFα were significantly downregulated in sarcoidosis compared to controls (p < 0.05). The ROC curve from the model showed a reasonable discriminatory ability of CD55 and TNFα to distinguish between sarcoidosis and controls with an AUC of 0.86. There was no combination of genes that could accurately differentiate between CBD and BeS or sarcoidosis phenotypes. Interpretation CD55, TNFα and CXCL9 expression levels can accurately differentiate between CBD and sarcoidosis, while CD55 and TNFα expression levels can accurately differentiate sarcoidosis and controls.

Indexed as

AdultAgedBerylliosisBiomarkersCD55 AntigensChemokine CXCL9Chronic DiseaseDiagnosis, DifferentialEosinophil Cationic ProteinFemaleGene ExpressionGene Expression RegulationGenetic MarkersHumansInterferon-gammaMaleBiomarkersCD55 AntigensChemokine CXCL9CXCL9 protein, humanEosinophil Cationic ProteinGenetic MarkersInterferon-gammaTumor Necrosis Factor-alphaChronic beryllium diseaseGene expressionGenomic biomarkersGranulomatous lung diseaseSarcoidosis

Identifiers

PMID34399367
PMCPMC8490480
OpenAlexW3143147898

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.